$CDLX

CDLX (NASDAQ: CDLX) files Form 144 for 40,296-share resale tied to vesting

Cardlytics, Inc. (NASDAQ: CDLX) has filed Form 144, indicating a proposed resale of 40,296 shares of Common Stock. This resale is linked to Restricted Stock Vesting that occurred on March 31, 2026. The filing also notes a previous sale of 6,253 shares by Nicholas H. Lynton on January 5, 2026.

Original reporting
Published Apr 1, 2026, 7:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$CDLXNeutralMed
01

Why it matters

The insider resale may temporarily increase stock supply, potentially leading to a short-term price decline. Market perception will depend on broader investor sentiment and overall trading volume.

02

Market read

While the insider sale is noteworthy, it is a routine event and unlikely to cause significant long-term impact unless accompanied by other negative signals.

03

What to watch

Market conditions, overall sector performance, and upcoming company fundamentals or earnings reports could mitigate or amplify the impact of insider activity.

Relevance 6/10Timing: Immediate (within days)

Background

Cardlytics filed Form 144 indicating the sale of 40,296 shares, linked to vesting events that occurred on March 31, 2026. This follows a previous sale of 6,253 shares by Nicholas H. Lynton on January 5, 2026.

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

The filing indicates insider activity related to stock vesting and potential resale, which can influence stock supply and investor perception.

Expected impact

Moderate short-term decline of approximately 2-4%, depending on market conditions.

Evidence & confidence

Insider sales tied to vesting are common and do not necessarily indicate negative outlooks; however, increased supply can influence price dynamics, especially if accompanied by low trading volume.

Market effects

Potential short-term pressure on the technology and financial services sectors if multiple insider sales occur.

Limited; primarily affects the NASDAQ and related regional indices.

Negligible; the event is company-specific and does not impact global markets.

Counterpoint

Insider sales tied to vesting may be routine and not indicative of negative sentiment; the stock could remain stable or rebound after initial sell-off.

Key entities

  • Cardlytics, Inc.

    A marketing technology company that provides purchase intelligence and marketing automation solutions.

  • Nicholas H. Lynton

    A director or executive of Cardlytics involved in the previous sale.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

$GMMed

GM’s Electric Vehicle Sales Fell Off A Cliff Last Quarter

General Motors reported a significant decline in U.S. EV sales in Q3, with Cadillac, Chevrolet, and GMC brands all seeing drops. Cadillac's total sales fell 30% to 32,650. Chevrolet's sales declined 4.6% to 437,321, with the Equinox EV down 92.4%. GMC's Hummer EV sales dropped 72.9%. Overall, GM's Q3 sales fell 5.5% to 670,974, and year-to-date sales are down 6.4%.

$GMMed

GM’s U.S. EV Sales Plunge 61.7% in Q3 2026

GM's U.S. EV sales dropped 61.7% YoY in Q3 2026 to 25,473 units, accounting for 3.8% of total sales. Overall sales fell 5.5%, with GM citing a smaller EV market. Cadillac's EVs performed relatively better, while models like Equinox EV saw steep declines. Ford also reported an 80% YoY EV sales drop.